糖尿病是缺血性脑卒中的重要危险因素之一,钠葡萄糖协同转运蛋白抑制剂作为一种新型的降糖药可通过抑制肾脏血管对葡萄糖吸收而起到控制血糖作用,同时有抑制动脉粥样硬化、降脂及减轻体重等功能。本文通过从钠–葡萄糖协同转运蛋白2抑...糖尿病是缺血性脑卒中的重要危险因素之一,钠葡萄糖协同转运蛋白抑制剂作为一种新型的降糖药可通过抑制肾脏血管对葡萄糖吸收而起到控制血糖作用,同时有抑制动脉粥样硬化、降脂及减轻体重等功能。本文通过从钠–葡萄糖协同转运蛋白2抑制剂作用机制出发,结合既往基础及临床研究报告。对钠–葡萄糖协同转运蛋白2抑制剂对缺血性脑血管病的影响及作用机制作一简要综述。Diabetes mellitus is one of the most important risk factors for ischemic stroke. Sodium-glucose cotransporter protein inhibitors, as a new type of hypoglycemic drugs, can control blood glucose by inhibiting glucose uptake by renal blood vessels, and at the same time inhibit atherosclerosis, lower lipids and reduce body weight. In this paper, the mechanism of sodium-glucose cotransporter protein 2 inhibitor is analyzed from the perspective of its mechanism of action, combined with the reports of previous basic and clinical studies. The effects of sodium-glucose cotransporter 2 inhibitors on ischemic cerebrovascular disease and its mechanism of action are briefly summarized.展开更多
文摘糖尿病是缺血性脑卒中的重要危险因素之一,钠葡萄糖协同转运蛋白抑制剂作为一种新型的降糖药可通过抑制肾脏血管对葡萄糖吸收而起到控制血糖作用,同时有抑制动脉粥样硬化、降脂及减轻体重等功能。本文通过从钠–葡萄糖协同转运蛋白2抑制剂作用机制出发,结合既往基础及临床研究报告。对钠–葡萄糖协同转运蛋白2抑制剂对缺血性脑血管病的影响及作用机制作一简要综述。Diabetes mellitus is one of the most important risk factors for ischemic stroke. Sodium-glucose cotransporter protein inhibitors, as a new type of hypoglycemic drugs, can control blood glucose by inhibiting glucose uptake by renal blood vessels, and at the same time inhibit atherosclerosis, lower lipids and reduce body weight. In this paper, the mechanism of sodium-glucose cotransporter protein 2 inhibitor is analyzed from the perspective of its mechanism of action, combined with the reports of previous basic and clinical studies. The effects of sodium-glucose cotransporter 2 inhibitors on ischemic cerebrovascular disease and its mechanism of action are briefly summarized.
